Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Market Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive ...
Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal ...
Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...
Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...
BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain inflammatory diseases. Ultomiris comes as a solution for intravenous (IV) infusion. It’s given by a healthcare professional, ...
Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an intravenous ...
Results from the trial were presented on April 5 at the 2022 American Academy of Neurology (AAN) Annual Meeting. gMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a ...
AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug that’s used for certain rare autoimmune conditions. The cost of Ultomiris with and without insurance can depend on several factors, such as whether ...
When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback